Home > Compound List > Product Information
Flunitrazepam_Molecular_structure_CAS_1622-62-4)
Click picture or here to close

Flunitrazepam

Catalog No. DB01544 Name DrugBank
CAS Number 1622-62-4 Website http://www.ualberta.ca/
M. F. C16H12FN3O3 Telephone (780) 492-3111
M. W. 313.2831832 Fax (780) 492-1071
Purity Email david.wishart@ualberta.ca
Storage Chembase ID: 1329

SYNONYMS

IUPAC name
5-(2-fluorophenyl)-1-methyl-7-nitro-2,3-dihydro-1H-1,4-benzodiazepin-2-one
IUPAC Traditional name
primun
Brand Name
Narcozep
Rohypnol
Roipnol
Primun
Synonyms
Flunitrazepamum [inn-latin]

DATABASE IDS

CAS Number 1622-62-4
PubChem SID 46504553
PubChem CID 3380

PROPERTIES

Hydrophobicity(logP) 2.06 [HANSCH,C ET AL. (1995)]

DETAILS

Description (English)
Item Information
Drug Groups illicit; approved
Description A benzodiazepine with pharmacologic actions similar to those of diazepam that can cause anterograde amnesia. Some reports indicate that it is used as a date rape drug and suggest that it may precipitate violent behavior. The United States Government has banned the importation of this drug. [PubChem]
Indication For short-term treatment of severe insomnias, that are not responsive to other hypnotics.
Pharmacology Flunitrazepam is a powerful hypnotic drug that is a benzodiazepine derivative. It has powerful hypnotic, sedative, anxiolytic, and skeletal muscle relaxant properties. The drug is sometimes used as a date rape drug. In the United States, the drug has not been approved by the Food and Drug Administration for medical use, and is considered to be an illegal drug. It has however been approved in the United Kingdom and other countries.
Toxicity Symptoms of overdose include confusion, coma, impaired coordination, sleepiness, and slowed reaction time.
Affected Organisms
Humans and other mammals
Biotransformation Hepatic.
Absorption 50% (suppository) and 64-77% (oral)
Half Life 18-26 hours
References
Rickels K: The clinical use of hypnotics: indications for use and the need for a variety of hypnotics. Acta Psychiatr Scand Suppl. 1986;332:132-41. [Pubmed]
Robertson MD, Drummer OH: Postmortem drug metabolism by bacteria. J Forensic Sci. 1995 May;40(3):382-6. [Pubmed]
Oelschlager H: [Chemical and pharmacologic aspects of benzodiazepines] Schweiz Rundsch Med Prax. 1989 Jul 4;78(27-28):766-72. [Pubmed]
Usami N, Yamamoto T, Shintani S, Ishikura S, Higaki Y, Katagiri Y, Hara A: Substrate specificity of human 3(20)alpha-hydroxysteroid dehydrogenase for neurosteroids and its inhibition by benzodiazepines. Biol Pharm Bull. 2002 Apr;25(4):441-5. [Pubmed]
Tokunaga S, Takeda Y, Shinomiya K, Hirase M, Kamei C: Effects of some H1-antagonists on the sleep-wake cycle in sleep-disturbed rats. J Pharmacol Sci. 2007 Feb;103(2):201-6. Epub 2007 Feb 8. [Pubmed]
External Links
Wikipedia

REFERENCES

  • Rickels K: The clinical use of hypnotics: indications for use and the need for a variety of hypnotics. Acta Psychiatr Scand Suppl. 1986;332:132-41. Pubmed
  • Oelschlager H: [Chemical and pharmacologic aspects of benzodiazepines] Schweiz Rundsch Med Prax. 1989 Jul 4;78(27-28):766-72. Pubmed
  • Usami N, Yamamoto T, Shintani S, Ishikura S, Higaki Y, Katagiri Y, Hara A: Substrate specificity of human 3(20)alpha-hydroxysteroid dehydrogenase for neurosteroids and its inhibition by benzodiazepines. Biol Pharm Bull. 2002 Apr;25(4):441-5. Pubmed
  • Tokunaga S, Takeda Y, Shinomiya K, Hirase M, Kamei C: Effects of some H1-antagonists on the sleep-wake cycle in sleep-disturbed rats. J Pharmacol Sci. 2007 Feb;103(2):201-6. Epub 2007 Feb 8. Pubmed
  • Robertson MD, Drummer OH: Postmortem drug metabolism by bacteria. J Forensic Sci. 1995 May;40(3):382-6. Pubmed